Having hot flashes
was associated with an 18 percent increased risk of diabetes.
Baseline characteristics were similar between groups, with no significant differences in frequency or severity of hot flashes
The idea to use magnesium oxide originated about six years ago when two pilot studies reported that doing so reduced the number and intensity of hot flashes
experienced by women taking either tamoxifen or aromatase inhibitors.
As part of this exploration, data from SWAN has been used to look at who has hot flashes
and why they last so long for some women.
developed in 20 (69%) women, with a median of 3.
In a racially, ethnically and geographically diverse group of 1,449 women with frequent hot flashes
or night sweats -- the largest study to date -- the median length of time women endured symptoms was 7.
The study included 120 women who had completed primary treatment for breast cancer and were having hot flashes
at least twice daily.
This book helps women reduce the number and intensity of hot flashes
caused by menopause, perimenopause, breast cancer treatment, and other conditions, using a five-week program of hypnosis based on the author's clinical research.
According to the study, there is a significant correlation between weight loss and hot flashes
and the degree of weight loss correlated with the degree of reduction in hot flashes
are the most common symptom of menopause and often the most bothersome.
The omega-3 fats DHA and EPA don't appear to curb hot flashes
in menopausal women, as earlier studies had suggested.
Food and Drug Administration on Friday approved a nonhormonal treatment for hot flashes
for the first time -- despite an outside advisory panel's previous determination that the drug in question was only a marginal improvement over placebo.
UKPRwire, Tue May 14 2013] Menopausal Hot Flashes
- Pipeline Review, H1 2013
QUESTION: "I've been asked for help by a friend with hot flashes
which have been plaguing her for two years.
Venlafaxine reduces hot flashes
more than placebo in women with a history of breast cancer; adverse effects include dry mouth and constipation (strength of recommendation [SOR]: B, randomized clinical trials [RCTs] with heterogeneous outcomes).